Progress and Challenges in
Transfusion Medicine, Hemostasis, and Hemotherapy

State of the Art 2008

41th Congress of the German Society for
Transfusion Medicine and Immunohematology

Editor
Rüdiger E. Scharf Düsseldorf

56 figures, 28 in color, 29 tables, 2008
Preface

Conferences come and go. They take more than one year to be prepared but are over within a couple of days. By contrast, research communications and ideas being exchanged among scientists have a longer half-life. Consequently, congress attendees wish to receive take-home messages. To satisfy this demand, this volume gathers the contributions of the Plenary Lectures and State-of-the-Art Symposia speakers who presented at the Joint Congress 2008 of the German Society for Transfusion Medicine and Immunohematology (DGTI) and the Interdisciplinary European Society for Hemapheresis and Hemotherapy (ESFH) in cooperation with the Société Française de Transfusion Sanguine (SFTS), held in Düsseldorf from September 16 through 19, 2008.

The idea of publishing a State-of-the-Art book concomitantly to a congress is not new. It was Professor Marc Verstraete, the doyen among the European scientists in the field of thrombosis and hemostasis, who promoted this activity some 20 years ago at the congress of the International Society of Thrombosis and Hemostasis (ISTH) in Brussels. Since then, a long-standing tradition has been established among the ISTH members. This paragon has now been adapted for the participants of this DGTI-ESFH-SFTS meeting.

In the foreword of the Brussels State-of-the-Art book, Professor Verstraete once wrote, ‘A preface is that part of a book that is placed first, written last, and read least’. Since all three statements he made are true, I will be brief. Transfusion medicine, hemostasis, and hemotherapy are relatively ‘young’ fields. They have in common both the subject ‘blood’ and the interdisciplinary approach. Thus, it is the translational impact of basic and clinical research that provides progress and challenges in patient care.

I am grateful to the authors, all experts in their field, who provided a chapter to this volume prior to the conference, meeting strict deadlines and accepting inevitable limitations in length, illustrations, and references. The support by our sponsors who made this project possible at all is particularly acknowledged, including CSL Behring, Wyeth, Baxter, NovoNordisk, and Novartis. Special thanks are also extended to the technical editing and production team of Karger publishers who worked hard to deliver this volume in due time. Finally, I would like to thank Uta Vandercappelle for her assistance, Nikola Möller for checking with me all manuscripts, and Anne Scharf for her coordination work as industrial liaison officer.

The editor hopes that the book will be received with the warmth and candor the authors deserve. To quote Professor Verstraete once more, ‘History will tell, but obviously, the history we learn depends on who is the historian’.  

Rüdiger E. Scharf, Düsseldorf
Contents

IX Preface

Social Intelligence and Competence

1 Increasing Safety by Implementing Optimized Team Interaction – Experiences of the Aviation Industry
Müller, M.H. (Frankfurt/Main)

Karl Landsteiner Lecture

15 Allogeneic Hematopoietic Cell Transplantation – 2008: Achievements and Challenges
Blume, K.G. (Stanford)

Organ- and Vascular Bed-Specific Thrombogenesis

24 Endothelium and Hemostasis in Health and Disease
Steffel, J.; Lüscher, T.F. (Zurich)

37 Intravascular and Extravascular Coagulation and Fibrinolysis in the Diseased Lung

48 Interaction of Platelets and Inflammatory Endothelium in the Development and Progression of Coronary Artery Disease
Langer, H.F.; Gawaz, M.P. (Tübingen)

Hemostasis in Infection and Host Defense

60 Infectious Agents, the Contact System, and Innate Immunity
Frick, I.-M.; Herwald, H. (Lund)

71 Fibrinolysis and Host Response in Bacterial Infections
Bergmann, S.; Hammerschmidt, S. (Munich)

Immunomodulation and Therapeutic Apheresis

89 Selective Immune Apheresis Technologies – Where Do We Stand?
Ramlow, W.; Prophet, H.; Emmrich, J. (Rostock)
113 Cytapheresis as a Nonpharmacological Therapy for Inflammatory Bowel Disease

123 Immunoadsorption in Dilated Cardiomyopathy
Staudt, A.; Felix, S.B. (Greifswald)

Stem Cells and Blood Cell Engineering

132 Therapeutic Use of Circulating Peripheral Blood Stem Cells
Haas, R.; Bruns, I.; Kobbe, G.; Kronenwett, R. (Düsseldorf)

151 Cultured Red Blood Cells: A New Advance in Stem Cell Engineering
Douay, L. (Paris)

162 From Hematopoietic Stem Cells to Megakaryocytes and Platelets
Favier, R. (Villejuif/Paris); Vainchenker, W. (Villejuif); Raslova, H. (Villejuif)

Molecular Immunohematology

178 The Bloodgen Project of the European Union
Avent, N.D. (Bristol)

189 Genotyping of Red Blood Cell, Granulocyte and Platelet Antigens: Current Applications in the German-Speaking Countries
Flegel, W.A. (Ulm); Wagner, F.F. (Springe)

199 Molecular Methods in Immunohematology: Use of the PCR-SSP Technique
Prager, M. (Lich)

209 Fetal Blood Group Genotyping
Seltsam, A. (Hanover)

Platelet-Pathogen Interactions

219 Innate Immunity of Platelets: Specific Interactions with Viruses
Flaujac, C. (Boulogne/Paris); Boukour, S. (Paris); Cramer Bordé, E. (Boulogne/Paris)

234 Bacterial Contamination of Platelet Components: Prevalence and Measures to Prevent Transfusion-Transmitted Bacterial Infection
Corash, L. (Concord)

248 Clinical Experience with Pathogen Inactivation of Platelet Components for Transfusion Support

Diagnosis and Management of Bleeding Disorders

264 Acute Bleeding Complications: Pathophysiology, Diagnosis and Management
Spannagl, M. (Munich)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>274</td>
<td>Challenges in Life-Threatening Hemorrhages: The Acquired Hemophilia</td>
<td>Stockschläder, M.; Scharf, R.E.</td>
<td>Düsseldorf</td>
</tr>
<tr>
<td>288</td>
<td>The Unrecognized von Willebrand Disease: A Frequent Cause of Bleeding Complications</td>
<td>Schneppenheim, R.; Budde, U.</td>
<td>Hamburg</td>
</tr>
<tr>
<td>296</td>
<td>Acquired Platelet Function Defects: An Underestimated but Frequent Cause of Bleeding Complications</td>
<td>Scharf, R.E.</td>
<td>Düsseldorf</td>
</tr>
</tbody>
</table>

**Genetic Research and Challenges in Thrombophilia**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>317</td>
<td>Past, Presence, and Future of Genetics in Thrombophilia</td>
<td>Reitsma, P.H.</td>
<td>Leiden</td>
</tr>
<tr>
<td>326</td>
<td>Thrombophilia and Vascular Complications in Pregnancy</td>
<td>Gerhardt, A.; Scharf, R.E.</td>
<td>Düsseldorf</td>
</tr>
<tr>
<td>344</td>
<td>Prevention and Therapy of Pregnancy-Associated Thromboembolic Events</td>
<td>Pabinger, I.</td>
<td>Vienna</td>
</tr>
</tbody>
</table>

**Novel Cellular Therapeutics**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>352</td>
<td>The Potential Role of Natural Killer Cells in the Treatment of Malignant Disease</td>
<td>Handgretinger, R.; Pfeiffer, M.; Teltschik, H.-M.; Feuchtinger, T.; Mueller, I.; Lang, P.</td>
<td>Tübingen</td>
</tr>
<tr>
<td>363</td>
<td>Current and Future Use of Dendritic Cells for Tolerance Induction</td>
<td>Hackstein, H.</td>
<td>Giessen</td>
</tr>
<tr>
<td>373</td>
<td>Adult and Embryonic Stem Cell Therapy</td>
<td>Hescheler, J.; Spitkovsky, D.</td>
<td>Cologne</td>
</tr>
</tbody>
</table>

**Hemostasis-Navigated Hemotherapy**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>385</td>
<td>Hemostasis-Navigated Hemotherapy: Diagnosis, Management, and Monitoring of Patients with Active Bleeding</td>
<td>Pötzsch, B. (Bonn); Scharf, R.E.</td>
<td>Düsseldorf</td>
</tr>
</tbody>
</table>

**Demographic Changes and Blood Supply**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>403</td>
<td>Author Index</td>
<td></td>
<td></td>
</tr>
<tr>
<td>405</td>
<td>Subject Index</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Λαμπ δια εχοντες διαδ σουσιν αλλ λοις  
’Having Light We Pass It On To Others’

Plato, ‘The Republic’, 328a
Conferences come and go. They take more than one year to be prepared but are over within a couple of days. By contrast, research communications and ideas being exchanged among scientists have a longer half-life. Consequently, congress attendees wish to receive take-home messages. To satisfy this demand, this volume gathers the contributions of the Plenary Lectures and State-of-the-Art Symposia speakers who presented at the Joint Congress 2008 of the German Society for Transfusion Medicine and Immunohematology (DGTI) and the Interdisciplinary European Society for Hemapheresis and Hemotherapy (ESFH) in cooperation with the Société Française de Transfusion Sanguine (SFTS), held in Düsseldorf from September 16 through 19, 2008.

The idea of publishing a State-of-the-Art book concomitantly to a congress is not new. It was Professor Marc Verstraete, the doyen among the European scientists in the field of thrombosis and hemostasis, who promoted this activity some 20 years ago at the congress of the International Society of Thrombosis and Hemostasis (ISTH) in Brussels. Since then, a long-standing tradition has been established among the ISTH members. This paragon has now been adapted for the participants of this DGTI-ESFH-SFTS meeting.

In the foreword of the Brussels State-of-the-Art book, Professor Verstraete once wrote, ‘A preface is that part of a book that is placed first, written last, and read least.’ Since all three statements he made are true, I will be brief. Transfusion medicine, hemostasis, and hemotherapy are relatively ‘young’ fields. They have in common both the subject ‘blood’ and the interdisciplinary approach. Thus, it is the translational impact of basic and clinical research that provides progress and challenges in patient care.

I am grateful to the authors, all experts in their field, who provided a chapter to this volume prior to the conference, meeting strict deadlines and accepting inevitable limitations in length, illustrations, and references. The support by our sponsors who made this project possible at all is particularly acknowledged, including CSL Behring, Wyeth, Baxter, NovoNordisk, and Novartis. Special thanks are also extended to the technical editing and production team of Karger publishers who worked hard to deliver this volume in due time. Finally, I would like to thank Uta Vandercappelle for her assistance, Nikola Möller for checking with me all manuscripts, and Anne Scharf for her coordination work as industrial liaison officer.

The editor hopes that the book will be received with the warmth and candor the authors deserve. To quote Professor Verstraete once more, ‘History will tell, but obviously, the history we learn depends on who is the historian.’

Rüdiger E. Scharf, Düsseldorf